ライフサイエンスコーパス: transbronchial

1 atients with sarcoidosis were studied (eight transbronchial, 27 lymph node, two skin, and two oral mu

2 ical and pathological testing (conjunctival, transbronchial and brain biopsies) to search for causes

3 Either bronchoscopy with transbronchial and endobronchial lung biopsies or endoso

4 ple logistic regression analysis, a positive transbronchial aspirate was associated only with a large

5 choscopy; (2) number, order, and location of transbronchial aspirates and results of on-site evaluati

6 gnancy increase the likelihood of a positive transbronchial aspiration; (4) USTBNA exhibits a similar

7 Airway inflammation in transbronchial biopsies (B score) correlated with NT in

8 Transbronchial biopsies (n=104) from 29 human lung trans

9 This retrospective study comprised all transbronchial biopsies (TBB) obtained during the first

10 evaluation and fiberoptic bronchoscopy with transbronchial biopsies and bronchoalveolar lavage exclu

11 Transbronchial biopsies are insufficiently sensitive to

12 CCSP-positive cells were assessed in transbronchial biopsies at 1 and 3 months.

13 Seventy-seven patients had transbronchial biopsies demonstrating BALT.

14 Transbronchial biopsies from 29 bronchoscopic procedures

15 Bronchoalveolar lavage (BAL) and transbronchial biopsies from 351 human immunodeficiency

16 Transbronchial biopsies from all lung transplant recipie

17 Longitudinal analysis of transbronchial biopsies from human lung transplant recip

18 CCSP+ve cells in transbronchial biopsies increased at 3 months only in LT

19 Transbronchial biopsies of patients receiving single lun

20 Retrospective chart review of all transbronchial biopsies performed within the first 2 yea

21 ular antigen-staining and rare bacilli while transbronchial biopsies showed granular antigen-staining

22 Transbronchial biopsies were also obtained when possible

23 Endobronchial and transbronchial biopsies were performed in selected patie

24 All transbronchial biopsies were regraded 0 to 4 for acute p

25 c diagnoses were made with 29 (34.9%) of the transbronchial biopsies, and patient management was chan

26 For messenger RNA in transbronchial biopsies, trends (p > 0.05 and <or= 0.10)

27 oscopy with bronchoalveolar lavage (BAL) and transbronchial biopsies.

28 by HRCT, whereas 35.2% had abnormalities on transbronchial biopsies.

29 Ab was determined at the same frequency with transbronchial biopsies.

30 of humoral immunity is a frequent finding on transbronchial biopsies.

31 onventional methods [BAL microbiological and transbronchial biopsy (TBB) analyses].

32 ografts using endobronchial biopsy (EBB) and transbronchial biopsy (TBB) from 22 lung transplant pati

33 study of consecutive patients who underwent transbronchial biopsy (TBBx) for evaluation of periphera

34 way endobronchial and distal alveolar tissue transbronchial biopsy in a random order at 4:00 P.M. and

35 way endobronchial and distal alveolar tissue transbronchial biopsy in a random order at 4:00 P.M. and

36 tologic associations with BALT identified on transbronchial biopsy in human lung allograft recipients

37 Transbronchial biopsy is performed, and pathology yields

38 the possibility that the presence of BALT on transbronchial biopsy may be part of the evolution of im

39 ance and 146 patients who underwent ENB with transbronchial biopsy of a lung lesion between 2013 and

40 bronchoscopist improved the success rate of transbronchial biopsy of subcarinal and aortopulmonary l

41 esently, histologic examination of tissue by transbronchial biopsy remains as the definitive diagnost

42 Transbronchial biopsy revealed adiaspores of the fungus

43 se samples (from 25 patients), corresponding transbronchial biopsy samples were available for CMV imm

44 Pathologic correlation between the transbronchial biopsy specimens and lung tissue obtained

45 sults were obtained in the endobronchial and transbronchial biopsy specimens, which consistently show

46 ults were compared with lavage and endo- and transbronchial biopsy studies in normal controls and pat

47 Transbronchial biopsy to sample lymph nodes and tumors t

48 Transbronchial biopsy was performed in 36 patients, of w

49 aluated by clinical history and examination, transbronchial biopsy, and high-resolution lung computed

50 We evaluated complications associated with transbronchial biopsy, diagnostic yield of the procedure

51 lop once disease recurrence had been seen on transbronchial biopsy.

52 s found to correlate with acute rejection by transbronchial biopsy.

53 treatable infection was diagnosed only with transbronchial biopsy.

54 esence or absence of acute lung rejection on transbronchial biopsy.

55 Messenger RNA in transbronchial lung biopsies and bronchoalveolar lavage

56 Histologic analysis of transbronchial lung biopsies demonstrated a few eosinoph

57 s, using bronchoalveolar lavage and repeated transbronchial lung biopsies to determine progression to

58 Bronchoscopy with transbronchial lung biopsies, the current diagnostic sta

59 acute rejection is diagnosed with the use of transbronchial lung biopsies, which are invasive, expens

60 tient management based on the results of the transbronchial lung biopsies.

61 id granuloma with noncaseating necrosis from transbronchial lung biopsy (TBLB) specimen, increasing o

62 omography findings alone and for considering transbronchial lung biopsy as a diagnostic tool.

63 Transbronchial lung biopsy can be performed with an acce

64 Eighty-three transbronchial lung biopsy procedures were performed in

65 umonia, or sepsis could be attributed to the transbronchial lung biopsy procedures.

66 of 45 tissue remodeling-associated genes in transbronchial lung biopsy specimens from two cohorts wi

67 allium scanning, bronchoalveolar lavage, and transbronchial lung biopsy.

68 gest there is a plateau in yield after seven transbronchial needle aspirates, which may be sufficient

69 tolerance of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) are based m

70 include endobronchial ultrasonography-guided transbronchial needle aspiration (EBUS-TBNA) biopsies of

71 l disease on endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in patients

72 The role of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in the clin

73 Real-time endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is an estab

74 Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is becoming

75 Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is establis

76 Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is increasi

77 em to either endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) or conventi

78 mputerized tomography (CT) of the chest with transbronchial needle aspiration (TBNA) in the staging o

79 Transbronchial needle aspiration (TBNA) of intrathoracic

80 In multivariate analysis, peripheral transbronchial needle aspiration (TBNA), larger lesion s

81 chieve a diagnosis as compared with standard transbronchial needle aspiration (TBNA).

82 ospectively confirm that ultrasound-directed transbronchial needle aspiration (USTBNA) results in: (1

83 to optimize yield, we prospectively studied transbronchial needle aspiration and the sequential effe

84 specimens acquired by endoscopic ultrasound transbronchial needle aspiration are sufficient for mole

85 ed to assess endobronchial ultrasound-guided transbronchial needle aspiration as an initial investiga

86 Transbronchial needle aspiration guided by endobronchial

87 (1) in the setting of on-site cytopathology, transbronchial needle aspiration has a high sensitivity,

88 Transbronchial needle aspiration has emerged as a key te

89 Concurrently, endoscopic ultrasound transbronchial needle aspiration has emerged as an accur

90 Endobronchial ultrasonography-guided transbronchial needle aspiration mediastinal staging (EB

91 A cytologically positive transbronchial needle aspiration occurred with the first

92 rgical exploration in patients with negative transbronchial needle aspiration; (4) sensitivity, speci

93 me reduction procedure for emphysema whereby transbronchial passages into the lung are created to rel

94 ome nanoparticle-enabled fluorescence-guided transbronchial photothermal therapy (PTT) of peripheral

95 Porphysomes also enhanced the efficacy of transbronchial PTT significantly and resulted in selecti

96 roviding real-time fluorescence guidance for transbronchial PTT.

97 s of concurrently obtained endobronchial and transbronchial/surgical biopsy tissue from 20 individual